PHASE III RANDOMIZED CONTROLLED TRIAL TO COMPARE BIOSIMILAR INFLIXIMAB (CT-P13) WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH ACTIVE CROHN’S DISEASE: 1-YEAR MAINTENANCE AND SWITCHING RESULTS

Young-Ho Kim  ¹     Byong Duk Ye  ²     Marina Pesegova  ³     Olga Alexeeva  ⁴     Marina Osipenko  ⁵     Adi Lahat  ⁶     Andriy Dorofeyev     Ágnes Szabone Salamon     Sigal Fishman     Olena Levchenko     Jae Hee Cheon     Maria Lia Scribano     Radu-Bogdan Mateescu     Kang Moon Lee     Chang Soo Eun     Sang Joon Lee     Sung Young Lee     Alex Kudrin    
¹ Samsung Medical Center,Seoul,Korea, Republic of
² Asan Medical Center,Seoul,Korea, Republic of
³ Krasnoyarsk Regional clinical hospital,Krasnoyarsk,Russian Federation
⁴ Nizhny Novgorod Regional Clinical Hospital,Nizhny Novgorod,Russian Federation
⁵ Novosibirsk State Medical University,Novosibirsk,Russian Federation
⁶ Sheba Medical Center,D

Conference
25th UEG Week 2017

Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)